Autoimmunity as a double agent in tumor killing and cancer promotion

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Toomer, Kevin H ^a   Chen, Zhibin ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Antitumor; Autoimmunity; Cytokine; Inflammation; Tumorigenesis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; PSEUDOMONAS EXOTOXIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOKINE RESPONSE; FEEDBACK SYSTEM; HELICOBACTER INFECTION; HELPER CELL; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; MELANOMA; MELANOMA B16; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TH17 CELL; TUMOR PROMOTION;

EID: 84897946330     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00116     Document Type: Review

References (150)

1. Miska J, Bas E, Devarajan P, Chen Z. Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self. Eur J Immunol (2012) 42:2584-2596. doi:10.1002/eji.201242590
2. Miska J, Devarajan P, Chen Z. The immunological identity of tumor: self implications. Oncoimmunology (2013) 2:e23794. doi:10.4161/onci.23794
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-45. doi:10.1016/S0140-6736(00)04046-0
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
5. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 7:95-106. doi:10.1038/nrc2051
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690
8. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366:2455-65. doi:10.1056/NEJMoa1200694
9. Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 10:1019-35. doi:10.1517/14712598.2010.482207
10. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2004) 75:163-89. doi:10.1189/jlb.0603252
11. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 13:95-109. doi:10.1016/S1359-6101(01)00038-7
12. Seliger B, Ruiz-Cabello F, Garrido F. IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res (2008) 101:249-76. doi:10.1016/S0065-230X(08)00407-7
13. Kelchtermans H, Billiau A, Matthys P. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol (2008) 29:479-86. doi:10.1016/j.it.2008.07.002
14. Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J Clin Invest (2007) 117:871-3. doi:10.1172/JCI31860
15. Stoicov C, Fan X, Liu JH, Bowen G, Whary M, Kurt-Jones E, et al. T-bet knockout prevents Helicobacter felis-induced gastric cancer. J Immunol (2009) 183:642-9. doi:10.4049/jimmunol.0900511
16. Syu LJ, El-Zaatari M, Eaton KA, Liu Z, Tetarbe M, Keeley TM, et al. Transgenic expression of interferon-gamma in mouse stomach leads to inflammation, metaplasia, and dysplasia. Am J Pathol (2012) 181:2114-25. doi:10.1016/j.ajpath.2012.08.017
17. Cho HI, Lee YR, Celis E. Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood (2011) 117:135-44. doi:10.1182/blood-2010-08-298117
18. Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest (2002) 110:1515-23. doi:10.1172/JCI200215564
19. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 72:3666-70. doi:10.1073/pnas.72.9.3666
20. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist (2006) 11:397-408. doi:10.1634/theoncologist.11-4-397
21. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis (2011) 70(Suppl 1):i104-8. doi:10.1136/ard.2010.140145
22. Gukovsky I, Li N, Todoric J, Gukovskaya A, Karin M. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology (2013) 144:1199.e-209.e. doi:10.1053/j.gastro.2013.02.007
23. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 140:197-208. doi:10.1016/j.cell.2009.12.052
24. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 9:361-71. doi:10.1038/nrc2628
25. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer (2010) 102:639-44. doi:10.1038/sj.bjc.6605530
26. Achyut BR, Bader DA, Robles AI, Wangsa D, Harris CC, Ried T, et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. PLoS Genet (2013) 9:e1003251. doi:10.1371/journal.pgen.1003251
27. Chaudhury A, Howe PH. The tale of transforming growth factor-beta (TGFbeta) signaling: a soigne enigma. IUBMB Life (2009) 61:929-39. doi:10.1002/iub.239
28. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol (2005) 6:600-7. doi:10.1038/ni1197
29. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest (2007) 87:1077-91. doi:10.1038/labinvest.3700669
30. Ramalingam R, Larmonier CB, Thurston RD, Midura-Kiela MT, Zheng SG, Ghishan FK, et al. Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J Immunol (2012) 189:3878-93. doi:10.4049/jimmunol.1201029
31. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol (2013) 228:1404-12. doi:10.1002/jcp.24260
32. Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, et al. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother (2009) 32:12-21. doi:10.1097/CJI.0b013e318189f13c
33. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell (2012) 22:291-303. doi:10.1016/j.ccr.2012.07.023
34. Yang L. TGFbeta and cancer metastasis: an inflammation link. Cancer Metastasis Rev (2010) 29:263-71. doi:10.1007/s10555-010-9226-3
35. Massague J. TGFbeta in cancer. Cell (2008) 134:215-30. doi:10.1016/j.cell.2008.07.001
36. Kurebayashi Y, Nagai S, Ikejiri A, Koyasu S. Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells (2013) 18:247-65. doi:10.1111/gtc.12039
37. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 10:248-56. doi:10.1038/nri2742
38. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol (2007) 178:7571-80.
39. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood (2009) 114:357-9. doi:10.1182/blood-2008-09-177360
40. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 31:787-98. doi:10.1016/j.immuni.2009.09.014
41. Nuñez S, Saez JJ, Fernandez D, Flores-Santibanez F, Alvarez K, Tejon G, et al. T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour. Immunology (2013) 139:61-71. doi:10.1111/imm.12055
42. Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P, et al. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother (2013) 62:1249-60. doi:10.1007/s00262-013-1429-3
43. Huang Z, van Velkinburgh JC, Ni B, Wu Y. Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B. Liver Int (2012) 32:894-901. doi:10.1111/j.1478-3231.2012.02764.x
44. Wu W, Li J, Chen F, Zhu H, Peng G, Chen Z. Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. J Gastroenterol Hepatol (2010) 25:750-7. doi:10.1111/j.1440-1746.2009.06154.x
45. Yang W, Ding X, Deng J, Lu Y, Matsuda Z, Thiel A, et al. Interferon-gamma negatively regulates Th17-mediated immunopathology during mouse hepatitis virus infection. J Mol Med (Berl) (2011) 89:399-409. doi:10.1007/s00109-010-0711-5
46. Ye Y, Xie X, Yu J, Zhou L, Xie H, Jiang G, et al. Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol (2010) 30:546-55. doi:10.1007/s10875-010-9416-3
47. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol (2010) 184:2281-8. doi:10.4049/jimmunol.0902574
48. Qian X, Gu L, Ning H, Zhang Y, Hsueh EC, Fu M, et al. Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol (2013) 190:5894-902. doi:10.4049/jimmunol.1203141
49. Baird AM, Leonard J, Naicker KM, Kilmartin L, O'Byrne KJ, Gray SG. IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer (2013) 79:83-90. doi:10.1016/j.lungcan.2012.10.003
50. Fukuda M, Ehara M, Suzuki S, Ohmori Y, Sakashita H. IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity. Int J Oncol (2010) 36:1355-65. doi:10.3892/ijo_00000620
51. Li J, Zhang L, Zhang J, Wei Y, Li K, Huang L, et al. Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. Carcinogenesis (2013) 34:658-66. doi:10.1093/carcin/bgs384
52. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 208:469-78. doi:10.1084/jem.20101876
53. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med (2007) 204:1037-47. doi:10.1084/jem.20061120
54. Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res (2012) 72:6338-43. doi:10.1158/0008-5472.CAN-12-3544
55. Koller FL, Hwang DG, Dozier EA, Fingleton B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis (2010) 31:1010-7. doi:10.1093/carcin/bgq044
56. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 1:389-402. doi:10.1016/j.stem.2007.08.001
57. Barderas R, Bartolome RA, Fernandez-Acenero MJ, Torres S, Casal JI. High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res (2012) 72:2780-90. doi:10.1158/0008-5472.CAN-11-4090
58. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res (2009) 69:8678-85. doi:10.1158/0008-5472.CAN-09-2100
59. Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer (2012) 131:344-56. doi:10.1002/ijc.26366
60. Virchow RLK. Cellular Pathology as based upon Physiological and Pathological Histology. Philadelphia: J. B. Lippincott (1863).
61. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9:162-74. doi:10.1038/nri2506
62. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 141:39-51. doi:10.1016/j.cell.2010.03.014
63. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 464:302-5. doi:10.1038/nature08782
64. He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res (2013) 73:629-39. doi:10.1158/0008-5472.CAN-12-2704
65. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 206:1457-64. doi:10.1084/jem.20090207
66. Devarajan P, Chen Z. Autoimmune effector memory T cells: the bad and the good. Immunol Res (2013) 57:12-22. doi:10.1007/s12026-013-8448-1
67. Germain RN, Robey EA, Cahalan MD. A decade of imaging cellular motility and interaction dynamics in the immune system. Science (2012) 336:1676-81. doi:10.1126/science.1221063
68. Miska J, Abdulreda MH, Devarajan P, Lui JB, Suzuki J, Pileggi A, et al. Real-time immune cell interactions in target tissue during autoimmune-induced damage and graft tolerance. J Exp Med (2014) 211:441-56. doi:10.1084/jem.20130785
69. Suzuki J, Ricordi C, Chen Z. Immune tolerance induction by integrating innate and adaptive immune regulators. Cell Transplant (2010) 19:253-68. doi:10.3727/096368909X480314
70. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol (2008) 108:415-20. doi:10.1016/j.ygyno.2007.10.016
71. Tano T, Okamoto M, Kan S, Nakashiro K, Shimodaira S, Koido S, et al. Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma. Neoplasia (2013) 15:305-14. doi:10.1593/neo.121528
72. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol (2013) 14:e218-28. doi:10.1016/S1470-2045(12)70582-X
73. Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med (1997) 186:695-704. doi:10.1084/jem.186.5.695
74. Hilburger Ryan M, Abrams SI. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother (2001) 49:603-12. doi:10.1007/s002620000156
75. Hu J, Kindsvogel W, Busby S, Bailey MC, Shi YY, Greenberg PD. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med (1993) 177:1681-90. doi:10.1084/jem.177.6.1681
76. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 160:643-51.
77. Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol (2008) 8:970-6. doi:10.1038/nri2438
78. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 23:6043-53. doi:10.1200/JCO.2005.06.205
79. Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol (2010) 2010:237623. doi:10.1155/2010/237623
80. Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res (2011) 17:6118-24. doi:10.1158/1078-0432.CCR-11-0482
81. Fojtova M, Boudny V, Kovarik A, Lauerova L, Adamkova L, Souckova K, et al. Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells. Br J Cancer (2007) 97:231-7. doi:10.1038/sj.bjc.6603849
82. Miller CH, Maher SG, Young HA. Clinical use of interferon-gamma. Ann N Y Acad Sci (2009) 1182:69-79. doi:10.1111/j.1749-6632.2009.05069.x
83. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, et al. Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 33:335-51. doi:10.1097/CJI.0b013e3181d32e74
84. Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol (2005) 2:90-7. doi:10.1038/ncponc0081 quiz 91 p following 113
85. Skurkovich B, Skurkovich S. Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. Curr Opin Mol Ther (2003) 5:52-7.
86. Skurkovich S, Skurkovich B, Kelly J. Anticytokine therapy, particularly anti-IFN-gamma, in Th1-mediated autoimmune diseases. Expert Rev Clin Immunol (2005) 1:11-25. doi:10.1586/1744666X.1.1.11
87. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest (2007) 117:60-9. doi:10.1172/JCI30111
88. Merchant JL. What lurks beneath: IL-11, via Stat3, promotes inflammation-associated gastric tumorigenesis. J Clin Invest (2008) 118:1628-31. doi:10.1172/JCI35344
89. Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer (2010) 10:403-14. doi:10.1038/nrc2857
90. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med (1997) 337:1441-8. doi:10.1056/NEJM199711133372007
91. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 124:1193-201. doi:10.1016/S0016-5085(03)00157-4
92. Judd LM, Alderman BM, Howlett M, Shulkes A, Dow C, Moverley J, et al. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology (2004) 126:196-207. doi:10.1053/j.gastro.2003.10.066
93. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell (2008) 14:408-19. doi:10.1016/j.ccr.2008.10.011
94. Weis VG, Goldenring JR. Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer (2009) 12:189-97. doi:10.1007/s10120-009-0527-6
95. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 100:655-69. doi:10.1016/S0092-8674(00)80702-3
96. Li X, McKinstry KK, Swain SL, Dalton DK. IFN-gamma acts directly on activated CD4+ T cells during mycobacterial infection to promote apoptosis by inducing components of the intracellular apoptosis machinery and by inducing extracellular proapoptotic signals. J Immunol (2007) 179:939-49.
97. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 8:74-80. doi:10.1038/nri2233
98. Tu SP, Quante M, Bhagat G, Takaishi S, Cui G, Yang XD, et al. IFN-gamma inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis. Cancer Res (2011) 71:4247-59. doi:10.1158/0008-5472.CAN-10-4009
99. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res (2009) 15:5308-16. doi:10.1158/1078-0432.CCR-07-5023
100. Bradley JR. TNF-mediated inflammatory disease. J Pathol (2008) 214:149-60. doi:10.1002/path.2287
101. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov (2003) 2:736-46. doi:10.1038/nrd1175
102. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spano F, Puppo F. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf (2012) 11:1-5. doi:10.1517/14740338.2012.630388
103. Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother (2001) 50:391-6.
104. Kruglov AA, Kuchmiy A, Grivennikov SI, Tumanov AV, Kuprash DV, Nedospasov SA. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev (2008) 19:231-44. doi:10.1016/j.cytogfr.2008.04.010
105. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med (1999) 5:828-31. doi:10.1038/10552
106. Fujiki H, Sueoka E, Suganuma M. Tumor promoters: from chemicals to inflammatory proteins. J Cancer Res Clin Oncol (2013) 139:1603-14. doi:10.1007/s00432-013-1455-8
107. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int (2013) 2013:187204. doi:10.1155/2013/187204
108. Natarajan M, Gibbons CF, Mohan S, Moore S, Kadhim MA. Oxidative stress signalling: a potential mediator of tumour necrosis factor alpha-induced genomic instability in primary vascular endothelial cells. Br J Radiol (2007) 80(1):S13-22. doi:10.1259/bjr/15316848
109. Pierce RH, Campbell JS, Stephenson AB, Franklin CC, Chaisson M, Poot M, et al. Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line. Am J Pathol (2000) 157:221-36. doi:10.1016/S0002-9440(10)64533-6
110. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation (2003) 107:1418-23. doi:10.1161/01.CIR.0000055318.09997.1F
111. Wheelhouse NM, Chan YS, Gillies SE, Caldwell H, Ross JA, Harrison DJ, et al. TNF-alpha induced DNA damage in primary murine hepatocytes. Int J Mol Med (2003) 12:889-94. doi:10.3892/ijmm.12.6.889
112. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell (2008) 134:392-404. doi:10.1016/j.cell.2008.07.025
113. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 90:770-4. doi:10.1073/pnas.90.2.770
114. Leveen P, Larsson J, Ehinger M, Cilio CM, Sundler M, Sjostrand LJ, et al. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood (2002) 100:560-8. doi:10.1182/blood.V100.2.560
115. Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep (2012) 28:615-21. doi:10.3892/or.2012.1822
116. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, et al. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res (2005) 7:R1058-79. doi:10.1186/bcr1343
117. Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res (2003) 63:1413-9.
118. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci (2012) 8:964-78. doi:10.7150/ijbs.4564
119. Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761. Cancer Res (2011) 71:2339-49. doi:10.1158/0008-5472.CAN-10-2941
120. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity (2009) 30:108-19. doi:10.1016/j.immuni.2008.11.009
121. Ye J, Livergood RS, Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol (2013) 182:10-20. doi:10.1016/j.ajpath.2012.08.041
122. Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature (2013) 496:461-8. doi:10.1038/nature11981
123. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 6:1123-32. doi:10.1038/ni1254
124. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 6:1133-41. doi:10.1038/ni1261
125. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol (2007) 28:207-12. doi:10.1016/j.it.2007.03.006
126. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol (2006) 27:17-23. doi:10.1016/j.it.2005.10.003
127. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol (2009) 183:4169-75. doi:10.4049/jimmunol.0901017
128. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13:715-25. doi:10.1016/S1074-7613(00)00070-4
129. Hatton RD. TGF-beta in Th17 cell development: the truth is out there. Immunity (2011) 34:288-90. doi:10.1016/j.immuni.2011.03.009
130. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature (2006) 442:461-5. doi:10.1038/nature04808
131. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets (2012) 11:159-68. doi:10.2174/187152812800392805
132. Van Dyken SJ, Locksley RM. Interleukin-4-and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol (2013) 31:317-43. doi:10.1146/annurev-immunol-032712-095906
133. Chapoval S, Dasgupta P, Dorsey NJ, Keegan AD. Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol (2010) 87:1011-8. doi:10.1189/jlb.1209772
134. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res (2012) 4:376-89.
135. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell (2008) 132:259-72. doi:10.1016/j.cell.2007.12.030
136. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev (2010) 19:46-54. doi:10.1183/09059180.00007609
137. Li Z, Jiang J, Wang Z, Zhang J, Xiao M, Wang C, et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res (2008) 68:8687-94. doi:10.1158/0008-5472.CAN-08-0449
138. Humphries A, Cereser B, Gay LJ, Miller DS, Das B, Gutteridge A, et al. Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc Natl Acad Sci U S A (2013) 110:E2490-9. doi:10.1073/pnas.1220353110
139. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science (2012) 337:730-5. doi:10.1126/science.1224676
140. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle (2008) 7:309-13. doi:10.4161/cc.7.3.5389
141. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol (2003) 111:677-90. doi:10.1067/mai.2003.1333 quiz 691
142. Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res (2010) 16:577-86. doi:10.1158/1078-0432.CCR-09-2015
143. Hall B, Nakashima H, Sun ZJ, Sato Y, Bian Y, Husain SR, et al. Targeting of interleukin-13 receptor alpha2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-beta and PTEN signaling. J Transl Med (2013) 11:45. doi:10.1186/1479-5876-11-45
144. Shimamura T, Husain SR, Puri RK. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus (2006) 20:E11. doi:10.3171/foc.2006.20.4.6
145. Mut M, Sherman JH, Shaffrey ME, Schiff D. Cintredekin besudotox in treatment of malignant glioma. Expert Opin Biol Ther (2008) 8:805-12. doi:10.1517/14712598.8.6.805
146. Ohka F, Natsume A, Wakabayashi T. Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int (2012) 2012:878425. doi:10.1155/2012/878425
147. Han D, Cai X, Wen J, Kenyon NS, Chen Z. From biomarkers to a clue of biology: a computation-aided perspective of immune gene expression profiles in human type 1 diabetes. Front Immunol (2012) 3:320. doi:10.3389/fimmu.2012.00320
148. Liseth K, Ersvaer E, Hervig T, Bruserud O. Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol (2010) 2010:692097. doi:10.1155/2010/692097
149. Finn OJ. Cancer immunology. N Engl J Med (2008) 358:2704-15. doi:10.1056/NEJMra072739
150. Braumüller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 494:361-5. doi:10.1038/nature11824